Marlan D. Walker - 18 Feb 2025 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)

Role
Chief Executive Officer
Signature
/s/ Marlan D. Walker
Issuer symbol
TXMD
Transactions as of
18 Feb 2025
Net transactions value
$0
Form type
4
Filing time
20 Feb 2025, 21:07:16 UTC
Previous filing
07 Dec 2023
Next filing
10 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXMD Common Stock Options Exercise $0 +3,467 +5.5% $0.000000 66,032 18 Feb 2025 Direct
transaction TXMD Common Stock Options Exercise $0 +2,311 +3.5% $0.000000 68,343 18 Feb 2025 Direct
transaction TXMD Common Stock Options Exercise $0 +770 +1.1% $0.000000 69,113 18 Feb 2025 Direct
transaction TXMD Common Stock Options Exercise $0 +1,733 +2.5% $0.000000 70,846 18 Feb 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXMD Performance Stock Units Options Exercise $0 -3,467 -100% $0.000000 0 18 Feb 2025 Common Stock 3,467 $0.000000 Direct F1
transaction TXMD Restricted Stock Units Options Exercise $0 -2,311 -100% $0.000000 0 18 Feb 2025 Common Stock 2,311 $0.000000 Direct F2
transaction TXMD Restricted Stock Units Options Exercise $0 -770 -100% $0.000000 0 18 Feb 2025 Common Stock 770 $0.000000 Direct F3
transaction TXMD Restricted Stock Units Options Exercise $0 -1,733 -50% $0.000000 1,733 18 Feb 2025 Common Stock 1,733 $0.000000 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance stock unit ("PSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 3,467 shares of common stock of the issuer in settlement of PSUs.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 2,311 shares of common stock of the issuer in settlement of RSUs, which vested on July 1, 2024.
F3 Each RSU represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 770 shares of common stock of the issuer in settlement of RSUs, which vested on September 29, 2024.
F4 Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. On February 18, 2025, the reporting person received 1,733 shares of common stock of the issuer in settlement of RSUs, which vested on March 23, 2024.